Chris Sweeney explains why the trial of atezolizumab and enzalutamide in patients with prostate cancer was negative and answers questions raised by the Uromigos.
Chris Sweeney explains why the trial of atezolizumab and enzalutamide in patients with prostate cancer was negative and answers questions raised by the Uromigos.